EmVenio Clinical Research Emerges as New Force in Patient-Centric Clinical Trials

EmVenio Clinical Research, a newly rebranded entity combining PCM Trials, EmVenio Research, and Clinical Trial Service, has announced its official launch. This strategic alignment aims to revolutionize clinical trial accessibility and patient engagement across the pharmaceutical industry.

Expanding Global Access to Clinical Research

EmVenio Clinical Research has established a significant global presence, operating in over 80 countries. The company's unique approach combines mobile visits, community-based research sites, and hospital-embedded locations to make trial participation more accessible and inclusive.

The organization's roots trace back to 2008 when PCM Trials was founded with the goal of improving clinical trial accessibility. Through a series of strategic acquisitions, including Clinical Trial Service in the Netherlands and EmVenio Research, the company has broadened its capabilities and reach.

Patient-Centric Approach to Clinical Trials

EmVenio's mission centers on meeting patients where they are – in their homes, communities, and local gathering places. This approach aims to remove barriers to participation and foster trust throughout the research journey.

The company's Certified Mobile Research Nurses network plays a crucial role in bringing therapies directly to patients who need them. Additionally, EmVenio's community-based research sites and brick-and-mortar centers within existing hospital systems, including the Prime Healthcare network, further enhance its ability to conduct diverse and representative clinical trials.

Enhancing Data Quality and Patient Retention

EmVenio Clinical Research emphasizes the importance of human connection in scientific advancement. The company reports industry-leading retention rates, which it attributes to its focus on building lasting relationships rooted in trust and empathy.

By tailoring research approaches to specific therapeutic areas and successfully enrolling patients from both routine and complex populations, EmVenio aims to provide clear, reliable data for every project. This patient-centric strategy not only improves the quality of clinical trial data but also contributes to a more comprehensive understanding of treatment efficacy across diverse populations.